What medicine can treat liver cancer? Check out the three commonly used medicines for liver cancer

There are many drugs for treating liver cancer. With the continuous advancement of medical technology, these drugs are also constantly changing. For example, sorafenib, regorafenib, and lenvatinib. The therapeutic effects of these three drugs are very similar and can prolong the patient's survival. However, there are indications and precautions when using the drugs, which must be mastered.

With the continuous improvement of medical standards, cancer treatment is also being innovated. Among many cancers, liver cancer has a particularly high mortality rate, which poses a great threat to the patient's life, and has also made many people pay attention to the treatment of liver cancer. Most patients diagnosed with advanced liver cancer have a survival period of less than two years. In addition, the drugs used to treat liver cancer in the past are not ideal and the efficacy is not very high. So what drugs are better for liver cancer now? The following gives a detailed answer.

1. Sorafenib (Nexavar)

This type of drug is a targeted drug, a multi-kinase inhibitor of tyrosine kinases such as RAF, vascular endothelial growth factor and pDGF, which can extend the patient's life by 2.8 months. According to relevant reports, the survival of patients with advanced liver cancer can be extended from 4.2 months to 6.5 months after taking sorafenib, and drug resistance will appear after about 4 months of medication.

2. Repaglinide

This product is a multi-target multi-kinase inhibitor. Repaglinide can significantly prolong the survival of liver cancer patients who have been treated with sorafenib before. Some patients can prolong their survival by 10.6 months after using this product. There is not much difference in the therapeutic effect between repaglinide and sorafenib. In addition, sorafenib is a first-line drug, while repaglinide is a second-line drug. There is also a problem of drug resistance during use.

3. Lenvatinib

This product is a multi-target kinase inhibitor that can block a series of tumor cell mutant genes, including vascular endothelial growth factor receptors 1-3, 1-4, etc. It is reported that in the process of treating liver cancer with lenvatinib or sorafenib, the overall survival can achieve the expected effect, and the progression-free survival or objective impact rate will exceed sorafenib, but side effects such as hypertension and diarrhea cannot be avoided.

The above article lists three drugs for treating liver cancer. Patients should understand the indications and precautions of the drugs when using them. For those who are not familiar with liver cancer, it is best to go to a regular hospital for diagnosis and treatment. To avoid adverse consequences, these drugs for treating liver cancer must not be purchased without permission. During the treatment, the patient's psychological emotions need to be adjusted. In order to prolong the life cycle, it is best to have an optimistic and confident attitude.